Drugs / Bentracimab
Bentracimab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05162131 | Dec 2021 → Dec 2022 | — | SFJ Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03492385 | Apr → Sep 2018 | — | SFJ Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03928353 | Apr → Oct 2019 | — | SFJ Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04286438 | Jul 2020 → Sep 2024 | hemorrhagic disease | SFJ Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04122170 Comparator | Sep 2019 → Sep 2021 | — | SFJ Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bentracimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05162131 ↗ |
| Known as | MEDI-2452 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594327 ↗ |
| Known as | PB2452 | “Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT Trial)” NCT04286438 ↗3“Bentracimab (PB2452) 18 g Intravenous Infusion over a 16 hour duration” NCT04122170 ↗ |
| Modality | Monoclonal antibody | “intravenous PB2452, a monoclonal antibody fragment that binds ticagrelor with high affinity” PMID 30883047 ↗ Mar 2019 |
| Route | Intravenous | “evaluated intravenous PB2452” PMID 30883047 ↗ Mar 2019 |